Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,752,761
  • Shares Outstanding, K 214,265
  • Annual Sales, $ 1,882 M
  • Annual Income, $ 109,490 K
  • 60-Month Beta 1.39
  • Price/Sales 8.59
  • Price/Cash Flow 69.20
  • Price/Book 8.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.25
  • Number of Estimates 2
  • High Estimate 0.33
  • Low Estimate 0.16
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +238.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.36 +0.91%
on 04/22/19
87.91 -16.94%
on 04/01/19
-13.00 (-15.11%)
since 03/25/19
3-Month
72.36 +0.91%
on 04/22/19
88.83 -17.80%
on 03/04/19
-6.93 (-8.67%)
since 01/25/19
52-Week
57.00 +28.11%
on 12/24/18
88.83 -17.80%
on 03/04/19
+10.03 (+15.92%)
since 04/25/18

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences

The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences

CHRS : 14.50 (-1.10%)
INCY : 73.13 (-0.53%)
MGTX : 18.70 (+1.36%)
ADRO : 3.51 (-1.68%)
The Zacks Analyst Blog Highlights: CommScope, Incyte, Cigna, Columbia Sportswear and Synopsys

The Zacks Analyst Blog Highlights: CommScope, Incyte, Cigna, Columbia Sportswear and Synopsys

COLM : 104.90 (-0.13%)
COMM : 25.40 (-3.68%)
CI : 153.00 (-0.79%)
SNPS : 118.96 (-0.76%)
INCY : 73.13 (-0.53%)
What's in Store for Vertex (VRTX) This Earnings Season?

On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.

CRSP : 39.28 (+1.84%)
VRTX : 172.23 (-0.20%)
INCY : 73.13 (-0.53%)
ADRO : 3.51 (-1.68%)
What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.

AMRN : 18.24 (-1.35%)
INCY : 73.13 (-0.53%)
GILD : 63.11 (+0.49%)
ADRO : 3.51 (-1.68%)
Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?

During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.

TRVN : 1.48 (+0.68%)
INCY : 73.13 (-0.53%)
GILD : 63.11 (+0.49%)
ADRO : 3.51 (-1.68%)
5 Biotech Stocks Defying the Medicare-for-All Scare

Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.

RARE : 68.01 (+0.41%)
INCY : 73.13 (-0.53%)
CHRS : 14.50 (-1.10%)
MGTX : 18.70 (+1.36%)
ADRO : 3.51 (-1.68%)
UNH : 228.68 (-0.72%)
Can S&P 500 and Nasdaq Sustain Record Run? 5 Top Picks

The broad-market S&P 500 Index and tech-laden Nasdaq Composite closed at an all-time high level yesterday.

COLM : 104.90 (-0.13%)
COMM : 25.40 (-3.68%)
CI : 153.00 (-0.79%)
SNPS : 118.96 (-0.76%)
INCY : 73.13 (-0.53%)
Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that the United States Patent and Trademark...

CNCE : 9.69 (+1.15%)
INCY : 73.13 (-0.53%)
ACRS : 6.64 (+3.91%)
Solid Earnings Boost S&P, NASDAQ to New Closing Highs

Solid Earnings Boost S&P, NASDAQ to New Closing Highs

NFLX : 369.19 (-1.35%)
TSLA : 253.85 (-1.86%)
LNG : 65.08 (-0.82%)
TWTR : 39.06 (-0.59%)
BIDU : 167.82 (-0.87%)
BMRN : 84.30 (-1.39%)
VRTX : 172.23 (-0.20%)
ARNC : 20.73 (-1.75%)
IONS : 73.34 (+0.01%)
INCY : 73.13 (-0.53%)
ADSW : 32.28 (-0.09%)
DS : 5.19 (+0.39%)
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on sales growth.

INCY : 73.13 (-0.53%)
TEVA : 14.88 (-0.80%)
AMGN : 177.95 (-0.20%)
PFE : 39.70 (+0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade INCY with:

Business Summary

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis...

See More

Key Turning Points

2nd Resistance Point 75.83
1st Resistance Point 74.68
Last Price 73.13
1st Support Level 72.91
2nd Support Level 72.29

See More

52-Week High 88.83
Fibonacci 61.8% 76.67
Last Price 73.13
Fibonacci 50% 72.92
Fibonacci 38.2% 69.16
52-Week Low 57.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar